Roberto Iacovelli

Sito Webhttps://docenti.unicatt.it/ppd2/linkPpdDocente?cod_docente=73799

Risultati di ricerca per anno

Settore disciplinare

MEDS-09/A - Oncologia medica

Fingerprint

Entra nei temi di ricerca in cui Roberto Iacovelli è attivo. Queste etichette tematiche provengono dalle opere di questa persona. Insieme formano una fingerprint unica.

1 Profili simili

Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study
Iacovelli, R., Ciccarese, C., Buti, S., Zucali, P. A., Fantinel, E., Bimbatti, D., Verzoni, E., Accettura, C., Bonomi, L., Buttigliero, C., Fornarini, G., Pipitone, S., Atzori, F., Masini, C., Massari, F., Primi, F., Strusi, A., Giudice, G. C., Perrino, M. & Maruzzo, M. e altri 5, Milella, M., Giannarelli, D., Brunelli, M., Procopio, G. & Tortora, G., 2024, In: European Urology. 86, 5, pag. 411-419 9 pag.
Risultato della ricerca: Contributo in rivista › Articolo
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Peltola, K., De, V. G., Burotto, M., Suarez, C., Ghatalia, P., Iacovelli, R., Lam, E. T., Verzoni, E., Gumus, M., Stadler, W. M., Kollmannsberger, C., Melichar, B., Venugopal, B., Gross-Goupil, M., Poprach, A., De, S. M., Schutz, F. A. & Park, S. H. e altri 13, Nosov, D. A., Porta, C., Lee, J. L., Garcia-Del-Muro, X., Biscaldi, E., Manneh, K. R., Oya, M., He, L., Wang, A., Perini, R. F., Vickery, D., Albiges, L. & Rini, B., 2024, In: THE NEW ENGLAND JOURNAL OF MEDICINE. 391, 8, pag. 710-721 12 pag.
Risultato della ricerca: Contributo in rivista › Articolo
Comparison of PIV and Other Immune Inflammation Markers of Oncological and Survival Outcomes in Patients Undergoing Radical Cystectomy
Russo, P., Palermo, G., Iacovelli, R., Ragonese, M., Ciccarese, C., Maioriello, G., Fantasia, F., Bizzarri, F. P., Marino, F., Moosavi, K., Nigro, D., Filomena, G. B., Gavi, F., Rossi, F., Pinto, F., Racioppi, M. & Foschi, N., 2024, In: Cancers. 16, 3, pag. N/A-N/A
Risultato della ricerca: Contributo in rivista › Articolo
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Massari, F., Santoni, M., Takeshita, H., Okada, Y., Tapia, J. C., Basso, U., Maruzzo, M., Scagliarini, S., Büttner, T., Fornarini, G., Myint, Z. W., Galli, L., Souza, V. C., Pichler, R., De Giorgi, U., Gandur, N., Lam, E. T., Gilbert, D., Popovic, L. & Grande, E. e altri 77, Mammone, G., Berardi, R., Crabb, S. J., Kemp, R., Molina-Cerrillo, J., Freitas, M., Luz, M., Iacovelli, R., Calabrò, F., Tural, D., Atzori, F., Küronya, Z., Chiari, R., Campos, S., Caffo, O., Fay, A. P., Kucharz, J., Zucali, P. A., Rinck, J. A., Zeppellini, A., Bastos, D. A., Aurilio, G., Mota, A., Trindade, K., Ortega, C., Sade, J. P., Rizzo, M., Fiala, O., Vau, N., Giannatempo, P., Barillas, A., Monteiro, F. S. M., Dauster, B., Mennitto, A., Nogueira, L., De Carvalho Fernandes, R., Seront, E., Aceituno, L. G., Grillone, F., Cutuli, H. J., Fernandez, M., Bassanelli, M., Kopp, R. M., Roviello, G., Abahssain, H., Procopio, G., Milella, M., Kopecky, J., Martignetti, A., Messina, C., Caitano, M., Inman, E., Kanesvaran, R., Herchhorn, D., Santini, D., Bamias, A., Bisonni, R., Mosca, A., Morelli, F., Maluf, F., Soares, A., Nunes, F., Pinto, A., Zgura, A., Incorvaia, L., Ansari, J., Zabalza, I. O., Landmesser, J., Rizzo, A., Mollica, V., Marchetti, A., Rosellini, M., Sorgentoni, G., Battelli, N., Buti, S., Porta, C. & Bellmunt, J., 2024, In: Cancer Immunology, Immunotherapy. 73, pag. 1-13 13 pag.
Risultato della ricerca: Contributo in rivista › Articolo
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Santoni, M., Buti, S., Myint, Z. W., Maruzzo, M., Iacovelli, R., Pichler, M., Kopecky, J., Kucharz, J., Rizzo, M., Galli, L., Büttner, T., De Giorgi, U., Kanesvaran, R., Fiala, O., Grande, E., Zucali, P. A., Kopp, R. M., Fornarini, G., Bourlon, M. T. & Scagliarini, S. e altri 46, Molina-Cerrillo, J., Aurilio, G., Matrana, M. R., Pichler, R., Cattrini, C., Büchler, T., Massari, F., Seront, E., Calabrò, F., Pinto, A., Berardi, R., Zgura, A., Mammone, G., Ansari, J., Atzori, F., Chiari, R., Bamias, A., Caffo, O., Procopio, G., Sunela, K., Bassanelli, M., Ortega, C., Grillone, F., Landmesser, J., Milella, M., Messina, C., Küronya, Z., Mosca, A., Bhuva, D., Santini, D., Vau, N., Morelli, F., Incorvaia, L., Rebuzzi, S. E., Roviello, G., Soares, A., Bisonni, R., Bimbatti, D., Zabalza, I. O., Rizzo, A., Mollica, V., Sorgentoni, G., Monteiro, F. S. M., Battelli, N., Bracarda, S. & Porta, C., 2024, In: European urology oncology. 7, pag. 102-111 10 pag.
Risultato della ricerca: Contributo in rivista › Articolo

The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis
Ciccarese, C. (Creatore), Anghelone, A. (Creatore), Stefani, A. (Creatore), Cigliola, A. (Creatore), Strusi, A. (Creatore), Bria, E. (Creatore), Iacovelli, R. (Creatore) & Tortora, G. (Creatore), Taylor & Francis, 2024
DOI: 10.6084/m9.figshare.26046130, https://tandf.figshare.com/articles/dataset/The_incidence_and_relative_risk_of_major_adverse_cardiovascular_events_and_hypertension_in_patients_treated_with_immune_checkpoint_inhibitors_plus_tyrosine-kinase_inhibitors_for_solid_tumors_a_systemic_review_and_meta-analysis/26046130
Dataset: Set di dati
The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis
Ciccarese, C. (Creatore), Anghelone, A. (Creatore), Stefani, A. (Creatore), Cigliola, A. (Creatore), Strusi, A. (Creatore), Bria, E. (Creatore), Iacovelli, R. (Creatore) & Tortora, G. (Creatore), Taylor & Francis, 2024
DOI: 10.6084/m9.figshare.26046130.v1, https://tandf.figshare.com/articles/dataset/The_incidence_and_relative_risk_of_major_adverse_cardiovascular_events_and_hypertension_in_patients_treated_with_immune_checkpoint_inhibitors_plus_tyrosine-kinase_inhibitors_for_solid_tumors_a_systemic_review_and_meta-analysis/26046130/1
Dataset: Set di dati

Roberto Iacovelli

Profilo personale

Settore disciplinare

Fingerprint

Collaborazioni e aree di ricerca di punta degli ultimi cinque anni

Entra nei dettagli

Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

Comparison of PIV and Other Immune Inflammation Markers of Oncological and Survival Outcomes in Patients Undergoing Radical Cystectomy

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study

Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis

The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis

Roberto Iacovelli

Profilo personale

Settore disciplinare

Fingerprint

Collaborazioni e aree di ricerca di punta degli ultimi cinque anni

Risultato della ricerca

Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

Comparison of PIV and Other Immune Inflammation Markers of Oncological and Survival Outcomes in Patients Undergoing Radical Cystectomy

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study

Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

Dataset

The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis

The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis